1. Israel Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Rekah Pharmaceutical Industry Ltd.

Rekah Pharmaceutical Industry Ltd.

TTASE:REKA
1,034.00
ILA
-10.00
(-0.96%)
-140.47EPS
12.17BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
49.42
39.6
25.01
22.75
20.92
18.19
17.21
23.26
23.12
25.62
28.18
28.18
26.37
27.01
Basic EPS, GAAP
1.52
-0.09
0.32
-1.15
-2.62
0.64
0.35
0.95
0.58
-0.18
-0.61
0.54
-1.58
-1.4
Free Cash Flow per Basic Share
1.34
-3.28
-0.88
0.98
0.76
0.19
-1.01
-0.66
0.63
2.76
1.45
1.56
0.51
2.03
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.88
- -
- -
- -
- -
Book Value per Share
- -
13.97
12.81
10.99
15.11
13.26
13.59
14.5
15.16
14.19
13.63
14.19
12.63
12.28
Tangible Book Value per Share
- -
13.45
12.7
10.72
14.86
13.07
13.38
14.14
12.27
11.05
7.77
8.86
7.7
7.52
Basic Weighted Avg Shares
5
5
8
10
10
11
11
11
11
11
11
11
11
11
Sales/Revenue/Turnover
270
216
210
218
201
199
196
265
264
292
322
322
301
304
Operating Margin (%)
2.46
2.04
3.23
3.41
6.57
8.2
6.75
7.87
5.1
5.14
1.67
-1.81
-2.08
-1.99
Depreciation Expense
7
8
9
10
10
11
17
20
23
27
30
33
31
30
Net Income, GAAP
8
-1
3
-11
-25
7
4
11
7
-2
-7
6
-18
-16
Effective Tax Rate (%)
26.78
- -
15.63
- -
- -
27.02
39.36
23.73
14.22
672.27
- -
21.72
- -
- -
Profit Margin (%)
3.08
-0.23
1.27
-5.04
-12.52
3.53
2.03
4.07
2.51
-0.7
-2.15
1.93
-6
-5.2
Working Capital
- -
89
138
134
114
117
93
119
123
104
108
71
81
71
LT Debt
- -
96
75
80
66
62
119
134
142
129
149
97
100
88
Total Equity
- -
77
124
106
145
151
155
166
173
162
156
162
144
140
Return on Invested Capital (%)
- -
- -
2.74
- -
- -
5.03
2.65
5.11
3.66
-23.45
- -
4.07
- -
- -
Return on Capital (%)
- -
- -
6.67
- -
- -
4.49
2.7
4.82
3.42
-10.48
- -
3.61
- -
- -
Return on Common Equity (%)
- -
- -
2.68
-9.63
-20.07
4.73
2.6
6.73
3.91
-1.22
-4.35
3.91
-11.81
- -

Capital Structure

ILS

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
33
40
35
LT Borrowings
69
63
59
LT Finance Leases
31
29
29
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
125
134
122

Working Capital

ILS

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
233
240
244
Cash, Cash Equivalents & STI
4
7
7
Accounts Receivable, Net
127
131
138
Inventories
91
93
96
Total Current Liabilities
152
164
173
Payables & Accruals
- -
- -
- -
ST Debt
33
40
35
Deferred Revenue
- -
- -
- -

Growth Rates

ILS

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.34%
-2.54%
-10.97%
Free Cash Flow
-96.23%
7.41%
-67.58%
Net Income, GAAP
-89.49%
-102.39%
-391.23%
Sales/Revenue/Turnover
4.27%
2.76%
-6.44%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

ILS

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
90
69
87
76
322
2025
76
- -
75
77
301
2026
79
73
- -
- -
- -

Quarterly Earnings Per Share

ILS

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.11
1.05
-0.39
-0.2
0.54
2025
-0.21
- -
-0.48
-0.55
-1.58
2026
-0.25
-0.12
- -
- -
- -

Quarterly Dividends Per Share

ILS

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Mordechai Algrably
Full Time Employees
421
Sector
Health technology
Industry
Pharmaceuticals: major
Address
30 Hamelach Street Holon TA Israel 5881904
IPO Date
Dec 14, 1995
Website
rekah.co.il
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Rekah Pharmaceutical Industries Ltd (REKA.TA) is an Israeli generic pharmaceuticals manufacturer engaged in the production, research and development, marketing, sales, distribution, import and export of pharmaceuticals, cosmetics, vitamins, nutritional supplements and medical devices. The company offers a comprehensive portfolio of approximately 400 generic Rx and OTC products across various therapeutic areas, including steroid tablets for anti-inflammatory treatments; antibiotics of the penicillin and cephalosporin families in capsules, suspensions and imported powders for intravenous and intramuscular use; ophthalmic products such as drops and ointments for allergies, infections, glaucoma, dryness and artificial tears; dermatological preparations; baby products; and over-the-counter remedies for urinary tract pain, cough, motion sickness, congestion, skin disinfection, wounds, fever, pain relief, depression, muscle pain, anemia and ear conditions; alongside dermo-cosmetics, herbal-based skin care and nutritional supplements through brands like Tree of Life and Moraz. Rekah operates two Good Manufacturing Practice-approved facilities in Holon and Binyamina, Israel, primarily serving the domestic market with exports to foreign markets, and maintains subsidiaries including Vita-med, Ophir & Shalpharm and Tree of Life. Founded in the early 1980s as a Jerusalem pharmacy and headquartered in Holon, Israel, the company listed on the Tel Aviv Stock Exchange in 1994 and pursued strategic growth including a 2021 acquisition of Tree of Life Pharma to expand into innovative medical devices and health products, alongside ongoing efforts in acquisitions, partnerships and European export preparations.